25 clinical trials
grid
list
download
Body (indexed field) | Identifiant (ID) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention | |||||
22720 | Participated in parent study | Thierry Berghmans | Multiple | Roche | IMBrella | Trial closed for recruitment | An open label, multicenter extension study in patients previously enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B) | 4 | 4 | ||
22662 | second line, RECIST 1.1, Biopsy | Philippe Aftimos | Multiple | Incyte Corporate | INCAGN1876-201 | Trial closed | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | philippe.aftimos@hubruxelles.be | 1 | 1 | |
22655 | Any line | Ahmad Hussein Awada | Solid tumors | Incyte Corporate | INCB59872-101 | Trial closed | A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
22849 | Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors | Solid tumors | Intervention destinée aux parents | Trial open for recruitment | L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité | ||||||
22828 | BRAF V600 mutation | Joseph Kerger | Skin | Roche | ML29741 | Trial closed | A Single Arm, Open Label, Phase II, Multicenter Study To Assess The Detection Of The Braf V600 Mutation On cfDNA From Plasma In Patients With Advanced Melanoma | joseph.kerger@hubruxelles.be | 2 | 2 | |
22675 | Any line/RECIST v1.1/Eligible for platinium salt chemotherapy | Nuria Kotecki | Multiple | Onxeo | OX2016-203-01 | Trial closed | An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
22819 | Available tumor tissue | Martine Piccart | Multiple | Institut Jules Bordet | PRECISION | Trial closed | The Jules Bordet Institute Program for Molecular Profiling of Metastatic Lesions : Feasibility | martine.piccart@hubruxelles.be | |||
22848 | Smoker of quit smoking within the last 6 months, any tumors | Solid tumors | Institut Jules Bordet | Sevrage Tabagique | Trial open for recruitment | Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomized study | |||||
23023 | RECIST v1.1 | Philippe Aftimos | Multiple | Synthon Biopharmaceuticals | SYD985.004 | Trial closed for recruitment | A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours | philippe.aftimos@hubruxelles.be | 1 | 1 | |
29422 | Age >18 > 2 lines Prior treatment with Mogamulizumab Relapsed/refractory stage KIR3DL2 expression Ecog 0-2 |
Marie Maerevoet | Lymphoma | Innate Pharma SA | TELLOMAK | Trial closed for recruitment | TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multicohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma | marie.maerevoet@hubruxelles.be | 2 | 2 |